Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$47.41 USD
-0.95 (-1.96%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $47.42 +0.01 (0.02%) 6:00 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Apogee Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -83.99 | -39.79 | NA | NA | NA |
Depreciation/Amortization & Depletion | -3.07 | 0.00 | NA | NA | NA |
Net Change from Assets/Liabilities | 6.11 | 9.82 | NA | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | NA | NA | NA |
Other Operating Activities | 6.19 | 13.54 | NA | NA | NA |
Net Cash From Operating Activities | -74.76 | -16.43 | NA | NA | NA |
Property & Equipment | -0.17 | 0.00 | NA | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | NA | NA | NA |
Investments | -273.74 | 0.00 | NA | NA | NA |
Other Investing Activities | 0.00 | 0.00 | NA | NA | NA |
Net Cash from Investing Activities | -273.91 | 0.00 | NA | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 315.39 | 168.32 | NA | NA | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | NA | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | NA | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | NA | NA | NA |
Other Financing Activities | 0.00 | 0.00 | NA | NA | NA |
Net Cash from Financing Activities | 315.39 | 168.32 | NA | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | NA | NA | NA |
Net Change In Cash & Equivalents | -33.28 | 151.89 | NA | NA | NA |
Cash at Beginning of Period | 151.89 | 0.00 | NA | NA | NA |
Cash at End of Period | 118.61 | 151.89 | NA | NA | NA |
Diluted Net EPS | -3.36 | -16.16 | NA | NA | NA |
Fiscal Year End for Apogee Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -65.91 | -32.09 | -83.99 | -52.25 | -31.41 |
Depreciation/Amortization & Depletion | -5.69 | -2.68 | -3.07 | -0.23 | 0.00 |
Net Change from Assets/Liabilities | 0.23 | -1.31 | 6.11 | 3.58 | 3.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 10.43 | 4.45 | 6.19 | 3.89 | 2.39 |
Net Cash From Operating Activities | -60.94 | -31.64 | -74.76 | -45.01 | -25.13 |
Property & Equipment | -0.40 | -0.35 | -0.17 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -200.05 | -51.39 | -273.74 | -234.22 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -200.45 | -51.74 | -273.91 | -234.22 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 450.37 | 450.52 | 315.39 | 315.60 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -1.69 |
Net Cash from Financing Activities | 450.37 | 450.52 | 315.39 | 315.60 | -1.69 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 188.98 | 367.14 | -33.28 | 36.38 | -26.82 |
Cash at Beginning of Period | 118.61 | 118.61 | 151.89 | 151.89 | 151.89 |
Cash at End of Period | 307.59 | 485.75 | 118.61 | 188.27 | 125.07 |
Diluted Net EPS | -0.60 | -0.64 | -0.32 | -0.51 | -3.78 |